Cancer initiation and proliferation is regulated by both epigenetic and genetic events with
epigenetic modifications being increasingly identified as important targets for cancer …

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible …

Purpose: Patients with acute myeloid leukemia (AML) frequently do not respond to
conventional therapies. Leukemic cell survival and treatment resistance have been …

Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …

Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid
malignancies have remained elusive. RNA-interference drug modifier screens identified …

DNA methylation plays a pivotal role in the etiology of cancer by mediating epigenetic
silencing of cancer-related genes. Since the relationship between aberrant DNA methylation …

Abstract Ribonucleotide reductase M2 (RRM2) is a small subunit in ribonucleotide
reductases, which participate in nucleotide metabolism and catalyze the conversion of …

Breast cancer is the most common cancer among females and the leading cause of cancer-
related deaths. Approximately 70% of breast cancers are estrogen receptor (ER) positive. An …

Genomic studies in acute myeloid leukemias (AML) have identified mutations that drive
altered DNA methylation, including TET2 and IDH2. Here, we show that models of AML …

CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA
methyltransferase inhibitor in clinical development for treatment of hematologic …